How effective is teclistamab and patient feedback summary

Teritolumab (Teclistamab) is a novel bispecific Tcell engager (BiTE) antibody, mainly used to treat relapsed or refractory multiple myeloma. It works by simultaneously targeting BCMA (B cell maturation antigen) and T on the surface of myeloma cells. CD3 molecules on the cell surface activate the patient's own T cells to recognize and kill tumor cells, thereby exerting a powerful anti-tumor effect. Clinical trials have shown that teritolumab has achieved significant results in improving survival and disease control in patients with multiple myeloma.

From an efficacy perspective, teritusumab showed a high overall response rate (ORR), and some patients even achieved complete remission (CR) or strict complete remission (sCR). Its therapeutic advantage lies in its ability to provide new treatment options for patients who have undergone multiple lines of treatment and for whom traditional therapies have failed. Data show that patients treated with teritusumab have delayed disease progression, significantly prolonged survival, and many patients have improved quality of life.

In terms of patient feedback, many patients said that after using teritusumab, their condition was under control, symptoms such as bone pain and fatigue were relieved, and their daily activities were restored. Since teritusumab is an injectable drug, some patients commented positively on the convenience of treatment, especially when the treatment effect is obvious and the patient compliance is good. However, some patients reported that some immune-related side effects may occur in the early stages of treatment, such as cytokine release syndrome (CRS), increased risk of infection, etc. However, most of these side effects can be effectively controlled through standardized management and preventive measures.

In summary, as an innovative immunotherapy drug, teritusumab has demonstrated good therapeutic effects and high patient satisfaction, and is especially suitable for patients with relapsed or refractory multiple myeloma. Although there is a certain risk of side effects, under the guidance of a professional medical team, through reasonable monitoring and supportive treatment, the patient's treatment experience and prognosis have been significantly improved. In the future, as more clinical data accumulates, teritusumab is expected to play an even more important role in the treatment system for multiple myeloma.

Reference materials:https://www.drugs.com/